Zhang-JianXin

An interventional radiologist & clinical oncologist

[Zhang-JianXin @windlemna]

@JacobPlieth HCC lesson so far: adding a 3rd systemic agent doesn't work (TRIPLET-HCC, IMbrave 152, EMERALD-3). But selectively adding locoregional therapy does (TALENTop, LAUNCH, NCT02774187, Kudo's ABC model). The path forward isn't more drugs — it's systemic + local.

[Zhang-JianXin @windlemna]

@SuyogCancer Endpoint choice depends on the treatment:
Novel mechanism, drug-free interval possible, OS too long to follow → use PFS.
Later-line moved upfront → use OS + mandatory crossover.

[Zhang-JianXin @windlemna]

@HeXiaoQi77 必要的时候还是就医看看。准备好一些可能的问题如：严重程度？是否伴咳嗽/发热？鼻涕是清的、稀的还是有颜色的、稠的？是不是反复发作？一天里面有没有时间规律？也可以准备短视频供参考。小儿的判断和变化会比成人复杂些，过敏性、腺样体（轻度时）、感染、鼻的问题等都有可能，也有的就是一过性。

[Zhang-JianXin @windlemna]

@AI_Jasonyu 那也算是个优势了。iPhone不用借助Android或写卡器。（大佬使用的时候是否有免费时限？在网页上没提到。）

[Zhang-JianXin @windlemna]

@whyeszhu 这两年报结果的研究太多了，指南于是赶紧都更新上来。

[Zhang-JianXin @windlemna]

@BenCreelan @BenjaminBesseMD Immunotherapy stops at 2 yrs in clinical trials. If discontinuation caused relapse, PFS should plummet after that — but it doesn't. This points more toward resistance than stopping treatment. No wonder rechallenge ORR isn't great.

[Zhang-JianXin @windlemna]

@ArndtVogel @HEP_Journal Neoadjuvant ≠ Conversion therapy. The former aims to minimize the risk of progression (ORR is not important!) , while the latter pursues a greater depth of response.

[Zhang-JianXin @windlemna]

@ChandrakanthMv Comparing concurrent vs. just the 1st step of sequential therapy is an unfair comparison. A positive PFS is no surprise, but it comes at the cost of losing a line of therapy for post-progression survival.

[Zhang-JianXin @windlemna]

@OscarTahuahua Did they use a placebo control? Both groups should ideally have morning and afternoon infusions to rule out bias. It’s a low-cost measure that would effectively control for the psychological and lifestyle impact of the infusion time itself.

[Zhang-JianXin @windlemna]

@DaisukeKotani @NatureMedicine Did they use a placebo control? Both groups should ideally have morning and afternoon infusions to rule out bias. It’s a low-cost measure that would effectively control for the psychological and lifestyle impact of the infusion time itself.

[Zhang-JianXin @windlemna]

@NiuSanford RTOG 1112 started at 2013. CARES-310 started at 2019. IMbrave 150 result was published at 2020. RTOG 1112 was early terminated at 2021 because of slow enrollment.

[Zhang-JianXin @windlemna]

@DrSwaroopOnco @ArndtVogel @TheLancetOncol The trial started at 2019, when sorafenib was the standard therapy.

[Zhang-JianXin @windlemna]

@DrRishabhOnco OK I've find it now. https://t.co/Q2ARdA648o

[Zhang-JianXin @windlemna]

@DrRishabhOnco I only find the preprint version:
DOI:10.20944/preprints202511.0021.v1

[Zhang-JianXin @windlemna]

@ArndtVogel @Cancer_Cell @grok Is this better than immuno-free therapy?

[Zhang-JianXin @windlemna]

@whyeszhu 能持续更新数据的研究可以有更多启发。这个研究OS的HR果然也降了。

[Zhang-JianXin @windlemna]

@radiology_rsna The two websites are same.

[Zhang-JianXin @windlemna]

@whyeszhu 从禁忌证出发这个推荐的思路更加倾向于免疫治疗。不过单纯免疫治疗的PD率还是要高于单纯靶向的，所以除了禁忌证之外，还得考虑对于短期内病情进展的容受性。

[Zhang-JianXin @windlemna]

@applelovecherr1 如果喜欢虾可考虑明月虾面（一家又小又旧的路边馆子）。
如果对蛋和肉有兴趣可以考虑灌蛋（一定程度上被视为收割游客的产品但是味道着实不错）。